Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTL201 oral cannabinoids for multiple sclerosis-related spasticity
MOH_2017-05-10_000359Phase 2Not yet recruiting
- Sponsor
- PhytoTech Therapeutics
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing PTL201 with Placebo (2 arms). Primary endpoints: Safety and Tolerability. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
PTL201
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2017-05-10_000359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-10_000359.